Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis
暂无分享,去创建一个
D. Centonze | G. Mandolesi | F. Buttari | A. Musella | A. Gentile | D. Fresegna | S. Bullitta | F. De Vito | M. Stampanoni Bassi | S. Caioli | F. Rizzo | V. Vanni | L. Guadalupi | Antonio Bruno | Ettore Dolcetti | Krizia Sanna | Sara Balletta
[1] D. Gomez-Nicola,et al. Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis , 2020, Journal of Neuroinflammation.
[2] S. Di Nuovo,et al. The cytokine network in the pathogenesis of major depressive disorder. Close to translation? , 2020, Autoimmunity reviews.
[3] D. Centonze,et al. ‘Prototypical’ proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting , 2020, Expert opinion on therapeutic targets.
[4] T. Bisogno,et al. Cannabinoids and the expanded endocannabinoid system in neurological disorders , 2019, Nature Reviews Neurology.
[5] J. Hillert,et al. Disability worsening among persons with multiple sclerosis and depression , 2019, Neurology.
[6] A. Araque,et al. In vivo knockdown of astroglial glutamate transporters GLT-1 and GLAST increases excitatory neurotransmission in mouse infralimbic cortex: Relevance for depressive-like phenotypes , 2019, European Neuropsychopharmacology.
[7] B. Barak,et al. Microglia roles in synaptic plasticity and myelination in homeostatic conditions and neurodevelopmental disorders , 2019, Glia.
[8] H. Ge,et al. Selecting an Appropriate Animal Model of Depression , 2019, International journal of molecular sciences.
[9] D. Centonze,et al. Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis , 2019, Front. Immunol..
[10] M. Hotopf,et al. Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. , 2019, Journal of psychosomatic research.
[11] V. Yong,et al. When encephalitogenic T cells collaborate with microglia in multiple sclerosis , 2019, Nature Reviews Neurology.
[12] F. Giuliani,et al. The Role of Inflammation in Depression and Fatigue , 2019, Front. Immunol..
[13] C. Peixoto,et al. Novel insights into the mechanisms underlying depression-associated experimental autoimmune encephalomyelitis , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[14] M. Ramanathan,et al. Epidemiology and treatment of multiple sclerosis in elderly populations , 2019, Nature Reviews Neurology.
[15] H. Okamura,et al. Interleukin-18-deficient mice develop hippocampal abnormalities related to possible depressive-like behaviors , 2019, Neuroscience.
[16] A. Bortolozzi,et al. Regionally selective knockdown of astroglial glutamate transporters in infralimbic cortex induces a depressive phenotype in mice , 2019, Glia.
[17] R. Hester,et al. Neuroprotective Benefits of Antidepressants in Multiple Sclerosis: Are We Missing the Mark? , 2019, The Journal of neuropsychiatry and clinical neurosciences.
[18] C. Pariante,et al. Microglial-driven changes in synaptic plasticity: A possible role in major depressive disorder , 2019, Psychoneuroendocrinology.
[19] R. Duman,et al. Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions , 2019, Front. Cell. Neurosci..
[20] J. Kool,et al. Influence of different rehabilitative aerobic exercise programs on (anti-) inflammatory immune signalling, cognitive and functional capacity in persons with MS – study protocol of a randomized controlled trial , 2019, BMC Neurology.
[21] A. Meissner,et al. T-Cell Accumulation in the Hypertensive Brain: A Role for Sphingosine-1-Phosphate-Mediated Chemotaxis , 2019, International journal of molecular sciences.
[22] S. Duan,et al. Cannabinoid CB1 receptors in the amygdalar cholecystokinin glutamatergic afferents to nucleus accumbens modulate depressive-like behavior , 2019, Nature Medicine.
[23] Bingqian Zhu,et al. Repetitive transcranial magnetic stimulation increases serum brain-derived neurotrophic factor and decreases interleukin-1β and tumor necrosis factor-α in elderly patients with refractory depression , 2019, The Journal of international medical research.
[24] S. Strother,et al. Cortical thickness in major depressive disorder: A systematic review and meta-analysis , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[25] P. Croarkin,et al. Transcranial Magnetic Stimulation for Adolescent Depression. , 2019, Child and adolescent psychiatric clinics of North America.
[26] Lin Yu,et al. Effect of selective serotonin reuptake inhibitor on prefrontal-striatal connectivity is dependent on the level of TNF-α in patients with major depressive disorder , 2018, Psychological Medicine.
[27] D. Centonze,et al. Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression , 2018, Front. Mol. Neurosci..
[28] R. G. Correa,et al. Dopamine: Functions, Signaling, and Association with Neurological Diseases , 2018, Cellular and Molecular Neurobiology.
[29] S. Patten,et al. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. , 2018, Multiple sclerosis and related disorders.
[30] A. Wróbel,et al. Cannabinoids in depressive disorders , 2018, Life sciences.
[31] J. Mann,et al. Depression , 2018, The Lancet.
[32] Y. Fang,et al. Effects of tumor necrosis factor-α polymorphism on the brain structural changes of the patients with major depressive disorder , 2018, Translational Psychiatry.
[33] A. Steptoe,et al. Depressive symptoms predict incident chronic disease burden 10 years later: Findings from the English Longitudinal Study of Ageing (ELSA). , 2018, Journal of psychosomatic research.
[34] S. Muthukumaraswamy,et al. Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis. , 2018, Journal of psychiatric research.
[35] M. Carta,et al. Pharmacological management of depression in patients with multiple sclerosis , 2018, Expert Opinion on Pharmacotherapy.
[36] M. Tremblay,et al. Reduced Microglial Activity and Enhanced Glutamate Transmission in the Basolateral Amygdala in Early CNS Autoimmunity , 2018, The Journal of Neuroscience.
[37] P. Calabresi,et al. Multiple sclerosis and cognition: synaptic failure and network dysfunction , 2018, Nature Reviews Neuroscience.
[38] P. Slominsky,et al. Genetics Factors in Major Depression Disease , 2018, Front. Psychiatry.
[39] E. Castrén,et al. Effects of the Antidepressant Fluoxetine on the Somatostatin Interneurons in the Basolateral Amygdala , 2018, Neuroscience.
[40] K. Seki,et al. Molecular mechanism of noradrenaline during the stress-induced major depressive disorder , 2018, Neural regeneration research.
[41] H. Steinbusch,et al. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression , 2018, Psychopharmacology.
[42] Adwitia Dey,et al. Insights into Macrophage Heterogeneity and Cytokine-Induced Neuroinflammation in Major Depressive Disorder , 2018, Pharmaceuticals.
[43] C. Baecher-Allan,et al. Effector T Cells in Multiple Sclerosis. , 2018, Cold Spring Harbor perspectives in medicine.
[44] F. Piehl,et al. Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers , 2018, Psychoneuroendocrinology.
[45] R. Edden,et al. Reduced GABA levels correlate with cognitive impairment in patients with relapsing-remitting multiple sclerosis , 2018, European Radiology.
[46] G. Gamberini,et al. Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment , 2018, CNS Drugs.
[47] R. Lu,et al. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder , 2018, Psychoneuroendocrinology.
[48] C. Pariante,et al. Repeated lipopolysaccharide exposure modifies immune and sickness behaviour response in an animal model of chronic inflammation , 2018, Journal of psychopharmacology.
[49] D. Centonze,et al. Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake , 2018, Journal of Neuroinflammation.
[50] A. Pastore,et al. Vortioxetine exerts anti‐inflammatory and immunomodulatory effects on human monocytes/macrophages , 2018, British journal of pharmacology.
[51] L. Steinman,et al. Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine , 2017, Journal of Neuroimmunology.
[52] D. Centonze,et al. Interferon-γ causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum , 2017, Neurobiology of Disease.
[53] D. Centonze,et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study) , 2017, Journal of Neurology.
[54] Li-Tao Yi,et al. microRNA-124 targets glucocorticoid receptor and is involved in depression-like behaviors , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[55] D. Centonze,et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis , 2017, Neurology.
[56] S. Nakagawa,et al. Neural basis of major depressive disorder: Beyond monoamine hypothesis , 2017, Psychiatry and clinical neurosciences.
[57] C. O. Brandão,et al. Suicidal ideation, anxiety, and depression in patients with multiple sclerosis , 2017, Arquivos de Neuro-Psiquiatria.
[58] S. Patten,et al. Depression in multiple sclerosis , 2017, International review of psychiatry.
[59] Lisa Koski,et al. GABA and glutamate levels correlate with MTR and clinical disability: Insights from multiple sclerosis , 2017, NeuroImage.
[60] Yong-Ku Kim,et al. The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder , 2017, Behavioural Brain Research.
[61] A. Bramanti,et al. Cortical Plasticity in Depression , 2017, ASN neuro.
[62] M. Keshavan,et al. The neurobiology of depression: An integrated view. , 2017, Asian journal of psychiatry.
[63] Simon Hametner,et al. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis , 2017, Brain : a journal of neurology.
[64] C. Wolfson,et al. Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. , 2017, International journal of MS care.
[65] B. Puri,et al. A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause? , 2017, Molecular Neurobiology.
[66] Allison C. Nugent,et al. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine , 2017, Biological Psychiatry.
[67] W. Wick,et al. Suppression of Th1 differentiation by tryptophan supplementation in vivo , 2017, Amino Acids.
[68] J. Sheridan,et al. Microglial recruitment of IL-1β producing monocytes to brain endothelium causes stress-induced anxiety , 2017, Molecular Psychiatry.
[69] S. Mathew,et al. Targeting glutamate signalling in depression: progress and prospects , 2017, Nature Reviews Drug Discovery.
[70] A. Carvalho,et al. Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders , 2017, Neuropsychopharmacology.
[71] M. Filippi,et al. Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis , 2017, Multiple sclerosis.
[72] Bruce V. Taylor,et al. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression , 2017, Scientific Reports.
[73] R. Marrie,et al. Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy: Using Explorys in the MS Population. , 2016, International journal of MS care.
[74] H. Lassmann,et al. Multiple sclerosis: experimental models and reality , 2016, Acta Neuropathologica.
[75] M. Maes,et al. Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation , 2016, Molecular Neurobiology.
[76] D. Mohr,et al. Major depressive disorder , 2016, Nature Reviews Disease Primers.
[77] D. Centonze,et al. Interaction between interleukin-1β and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis , 2016, Journal of Neuroinflammation.
[78] S. Lipton,et al. Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities , 2016, The Lancet Neurology.
[79] D. Feuerbach,et al. Antidepressant therapies inhibit inflammation and microglial M1-polarization. , 2016, Pharmacology & therapeutics.
[80] C. Limatola,et al. Fractalkine receptor deficiency impairs microglial and neuronal responsiveness to chronic stress , 2016, Brain, Behavior, and Immunity.
[81] M. Fakhoury. Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders , 2016, Molecular Neurobiology.
[82] Deborah M. Miller,et al. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial , 2016, Journal of the Neurological Sciences.
[83] S. Lévesque,et al. Myeloid cell transmigration across the CNS vasculature triggers IL-1β–driven neuroinflammation during autoimmune encephalomyelitis in mice , 2016, The Journal of experimental medicine.
[84] R. Dantzer. Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches. , 2016, Current topics in behavioral neurosciences.
[85] P. Santos. The role of inflammation in depression , 2016 .
[86] P. Ragonese,et al. A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study , 2016, Journal of the Neurological Sciences.
[87] S. Wood,et al. Neuroinflammation at the interface of depression and cardiovascular disease: Evidence from rodent models of social stress , 2016, Neurobiology of Stress.
[88] S. Russo,et al. Pathogenesis of depression: Insights from human and rodent studies , 2016, Neuroscience.
[89] Z. Baloch,et al. Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review , 2016, International journal of molecular sciences.
[90] R. Shelton,et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.
[91] R. Duman,et al. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. , 2016, Drug discovery today.
[92] Xia Zhang,et al. Role of neuroinflammation in neurodegenerative diseases (Review) , 2016, Molecular medicine reports.
[93] T. Olsson,et al. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms , 2016, Brain, Behavior, and Immunity.
[94] M. J. Bellizzi,et al. Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis , 2016, The Journal of Neuroscience.
[95] D. Centonze,et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis , 2015, Nature Reviews Neurology.
[96] L. Luo,et al. Organization of the Locus Coeruleus-Norepinephrine System , 2015, Current Biology.
[97] Klaus P. Ebmeier,et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder , 2015, Brain, Behavior, and Immunity.
[98] M. Furtado,et al. Examining the role of neuroinflammation in major depression , 2015, Psychiatry Research.
[99] D. Centonze,et al. The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission , 2015, Neuropharmacology.
[100] Manuel A. Friese,et al. Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.
[101] N. Toschi,et al. Structural ‘connectomic’ alterations in the limbic system of multiple sclerosis patients with major depression , 2015, Multiple sclerosis.
[102] D. Centonze,et al. Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis , 2015, Front. Cell. Neurosci..
[103] G. Aghajanian,et al. Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions , 2015, Proceedings of the National Academy of Sciences.
[104] P. Fox,et al. Identification of a common neurobiological substrate for mental illness. , 2015, JAMA psychiatry.
[105] V. De Rosa,et al. Animal models of Multiple Sclerosis , 2015, European Journal of Pharmacology.
[106] Q. Pittman,et al. Microglia-Dependent Alteration of Glutamatergic Synaptic Transmission and Plasticity in the Hippocampus during Peripheral Inflammation , 2015, The Journal of Neuroscience.
[107] Paul B Fitzgerald,et al. THETA‐BURST STIMULATION: A NEW FORM OF TMS TREATMENT FOR DEPRESSION? , 2015, Depression and anxiety.
[108] Alan A. Wilson,et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. , 2015, JAMA psychiatry.
[109] D. Centonze,et al. Dopaminergic dysfunction is associated with IL-1β-dependent mood alterations in experimental autoimmune encephalomyelitis , 2015, Neurobiology of Disease.
[110] Jingyuan Chen,et al. Microglia activation regulates GluR1 phosphorylation in chronic unpredictable stress-induced cognitive dysfunction , 2015, Stress.
[111] D. Centonze,et al. Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53 , 2014, Molecular Neurodegeneration.
[112] Peter B. Jones,et al. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. , 2014, JAMA psychiatry.
[113] A. Feinstein,et al. The link between multiple sclerosis and depression , 2014, Nature Reviews Neurology.
[114] G. Rosoklija,et al. Microglia of Prefrontal White Matter in Suicide , 2014, Journal of neuropathology and experimental neurology.
[115] Etienne Sibille,et al. Why Are Cortical GABA Neurons Relevant to Internal Focus in Depression? A cross-level model linking cellular, biochemical, and neural network findings , 2014, Molecular Psychiatry.
[116] D. Centonze,et al. Interleukin-1β Promotes Long-Term Potentiation in Patients with Multiple Sclerosis , 2014, NeuroMolecular Medicine.
[117] B. Giros,et al. Morphometric characterization of microglial phenotypes in human cerebral cortex , 2014, Journal of Neuroinflammation.
[118] G. Mead,et al. Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: systematic review and meta-analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[119] J. Nacher,et al. Chronic stress alters inhibitory networks in the medial prefrontal cortex of adult mice , 2013, Brain Structure and Function.
[120] S. Kirzinger,et al. Relationship between disease-modifying therapy and depression in multiple sclerosis. , 2013, International journal of MS care.
[121] Q. Pittman,et al. Altered cognitive-emotional behavior in early experimental autoimmune encephalitis – Cytokine and hormonal correlates , 2013, Brain, Behavior, and Immunity.
[122] G. Baker,et al. Fluoxetine and citalopram decrease microglial release of glutamate and d-serine to promote cortical neuronal viability following ischemic insult , 2013, Molecular and Cellular Neuroscience.
[123] D. Centonze,et al. Interleukin-1β Alters Glutamate Transmission at Purkinje Cell Synapses in a Mouse Model of Multiple Sclerosis , 2013, The Journal of Neuroscience.
[124] R. Torta,et al. Pharmacological Management of Depression in Patients with Cancer: Practical Considerations , 2013, Drugs.
[125] M. Banasr,et al. From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders , 2013, Biological Psychiatry.
[126] C. Benkelfat,et al. The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies† , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.
[127] P. Calabresi,et al. Effects of central and peripheral inflammation on hippocampal synaptic plasticity , 2013, Neurobiology of Disease.
[128] D. Centonze,et al. Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis , 2013, PloS one.
[129] R. McLaughlin,et al. Upregulation of CB1 receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure , 2013, Behavioural Brain Research.
[130] F. Kirchhoff,et al. Microglia: New Roles for the Synaptic Stripper , 2013, Neuron.
[131] D. Centonze,et al. TNF-α-mediated anxiety in a mouse model of multiple sclerosis , 2012, Experimental Neurology.
[132] T. Pickersgill,et al. Multiple sclerosis relapses and depression. , 2012, Journal of psychosomatic research.
[133] I. Craig,et al. Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors' and Longitudinal ‘Targets' , 2012, Neuropsychopharmacology.
[134] Laurent Descarries,et al. The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.
[135] R. Claycomb,et al. Interleukin-1β in Central Nervous System Injury and Repair. , 2012, European journal of neurodegenerative disease.
[136] R. Ransohoff,et al. Animal models of multiple sclerosis: the good, the bad and the bottom line , 2012, Nature Neuroscience.
[137] P. Piccini,et al. Imaging of Microglia in Patients with Neurodegenerative Disorders , 2012, Front. Pharmacol..
[138] D. Centonze,et al. GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis , 2012, Neurobiology of Disease.
[139] H. Son,et al. Neuropathological abnormalities of astrocytes, GABAergic neurons, and pyramidal neurons in the dorsolateral prefrontal cortices of patients with major depressive disorder , 2012, European Neuropsychopharmacology.
[140] J. Nacher,et al. Expression of PSA-NCAM and synaptic proteins in the amygdala of psychiatric disorder patients. , 2012, Journal of psychiatric research.
[141] G. Sanacora,et al. Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders , 2012, Neuropharmacology.
[142] D. Centonze,et al. Interleukin‐1β causes synaptic hyperexcitability in multiple sclerosis , 2012, Annals of neurology.
[143] E. Castrén,et al. Fear Erasure in Mice Requires Synergy Between Antidepressant Drugs and Extinction Training , 2011, Science.
[144] A. Teixeira,et al. Behavioral investigation of mice with experimental autoimmune encephalomyelitis. , 2011, Arquivos de neuro-psiquiatria.
[145] Zhen Yan,et al. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission , 2011, Nature Reviews Neuroscience.
[146] Gustavo Tenorio,et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE) , 2011, Brain, Behavior, and Immunity.
[147] Anthony Feinstein,et al. Multiple sclerosis and depression , 2011, Multiple sclerosis.
[148] P. Moore,et al. Endocannabinoid system dysfunction in mood and related disorders , 2011, Acta psychiatrica Scandinavica.
[149] Serge Marchand,et al. A Deficit in Peripheral Serotonin Levels in Major Depressive Disorder but Not in Chronic Widespread Pain , 2011, The Clinical journal of pain.
[150] G. Juckel,et al. Inflammation modulates anxiety in an animal model of multiple sclerosis , 2011, Behavioural Brain Research.
[151] C. Ionete,et al. Relationships between multiple sclerosis and depression. , 2011, The Journal of neuropsychiatry and clinical neurosciences.
[152] Massimiliano Calabrese,et al. Cortical pathology and cognitive impairment in multiple sclerosis , 2011, Expert review of neurotherapeutics.
[153] S. Janelidze,et al. Cytokine levels in the blood may distinguish suicide attempters from depressed patients , 2011, Brain, Behavior, and Immunity.
[154] Zheng Zachory Wei,et al. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. , 2011, Current Alzheimer research.
[155] M. Zappia,et al. Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study , 2010, Multiple sclerosis.
[156] R. Dantzer,et al. CSF Concentrations of Brain Tryptophan and Kynurenines during Immune Stimulation with IFN-alpha: Relationship to CNS Immune Responses and Depression , 2009, Molecular Psychiatry.
[157] Alessandro Martorana,et al. Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis , 2009, Neurobiology of Disease.
[158] Andrew H. Miller,et al. Cytokines and Glucocorticoid Receptor Signaling , 2009, Annals of the New York Academy of Sciences.
[159] Jing Du,et al. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. , 2009, The international journal of neuropsychopharmacology.
[160] Charles L. Raison,et al. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.
[161] D. Centonze,et al. Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis , 2009, The Journal of Neuroscience.
[162] D. Centonze,et al. Adaptations of Striatal Endocannabinoid System During Stress , 2009, Molecular Neurobiology.
[163] Sung‐Hwa Yoon,et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti‐inflammatory effect , 2009, Journal of neuroscience research.
[164] Jaclyn I. Wamsteeker,et al. Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis , 2009, Nature Neuroscience.
[165] G. Juckel,et al. Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment , 2009, Therapeutic advances in neurological disorders.
[166] H. Critchley,et al. Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans , 2008, Biological Psychiatry.
[167] S. Gwaltney-Brant,et al. Serotonin: a review. , 2008, Journal of veterinary pharmacology and therapeutics.
[168] M. van Buchem,et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[169] E. Maron,et al. Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[170] R. Belmaker,et al. Major depressive disorder. , 2008, The New England journal of medicine.
[171] M. Banasr,et al. Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. , 2007, CNS & neurological disorders drug targets.
[172] P. O’Connell,et al. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. , 2007, Blood.
[173] P. Scully,et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. , 2007, Journal of psychiatric research.
[174] R. Dantzer,et al. Named Series: Twenty Years of Brain, Behavior, and Immunity Twenty years of research on cytokine-induced sickness behavior , 2007 .
[175] Gregor Hasler,et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. , 2007, Archives of general psychiatry.
[176] Andrew H. Miller,et al. Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression , 2007, Brain, Behavior, and Immunity.
[177] A. Schene,et al. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies , 2007, Molecular Psychiatry.
[178] S. Gold,et al. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. , 2006, Neurologic clinics.
[179] D. Fuchs,et al. Monitoring tryptophan metabolism in chronic immune activation. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[180] M. McCabe. Mood and self-esteem of persons with multiple sclerosis following an exacerbation. , 2005, Journal of psychosomatic research.
[181] B. Bogerts,et al. Volume deficits of subcortical nuclei in mood disorders , 2005, European Archives of Psychiatry and Clinical Neuroscience.
[182] S. Khoury,et al. Cytokines in multiple sclerosis: from bench to bedside. , 2005, Pharmacology & therapeutics.
[183] George P Chrousos,et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. , 2005, The Journal of clinical endocrinology and metabolism.
[184] J. Francis,et al. Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia , 2005, Physiology & Behavior.
[185] W. Drevets,et al. Discovering Endophenotypes for Major Depression , 2004, Neuropsychopharmacology.
[186] M. Bear,et al. LTP and LTD An Embarrassment of Riches , 2004, Neuron.
[187] R. Spengler,et al. Brain-Derived Tumor Necrosis Factor-α and Its Involvement in Noradrenergic Neuron Functioning Involved in the Mechanism of Action of an Antidepressant , 2004, Journal of Pharmacology and Experimental Therapeutics.
[188] C. Pozzilli,et al. Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis , 2003, Multiple sclerosis.
[189] Y. Pollak,et al. The EAE-associated behavioral syndrome I. Temporal correlation with inflammatory mediators , 2003, Journal of Neuroimmunology.
[190] I. Goshen,et al. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of ‘depression due to multiple sclerosis’ , 2002, Brain, Behavior, and Immunity.
[191] E. Zorrilla,et al. The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review , 2001, Brain, Behavior, and Immunity.
[192] T. J. Nickola,et al. Antidepressant Drug-Induced Alterations in Neuron-Localized Tumor Necrosis Factor-α mRNA and α2-Adrenergic Receptor Sensitivity , 2001 .
[193] J. Kelly,et al. Olfactory Bulbectomy Provokes a Suppression of Interleukin-1β and Tumour Necrosis Factor-α Production in Response to an in vivo Challenge with Lipopolysaccharide: Effect of Chronic Desipramine Treatment , 1999, Neuroimmunomodulation.
[194] B. Roth,et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗ ∗ See accompanying Editorial, in this issue. , 1999, Biological Psychiatry.
[195] E. Bosmans,et al. Negative Immunoregulatory Effects of Antidepressants: Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion , 1999, Neuropsychopharmacology.
[196] Michael Maes,et al. Evidence for an immune response in major depression: A review and hypothesis , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[197] R. S. Smith. The macrophage theory of depression. , 1991, Medical hypotheses.
[198] D. Ditor,et al. The effects of acute aerobic exercise on mood and inflammation in individuals with multiple sclerosis and incomplete spinal cord injury. , 2019, NeuroRehabilitation.
[199] Yan Wang,et al. Behavioral defects induced by chronic social defeat stress are protected by Momordica charantia polysaccharides via attenuation of JNK3/PI3K/AKT neuroinflammatory pathway. , 2019, Annals of translational medicine.
[200] D. Reich,et al. Multiple Sclerosis , 2018, The New England journal of medicine.
[201] J. Meyer,et al. Neuroprogression and Immune Activation in Major Depressive Disorder. , 2017, Modern trends in pharmacopsychiatry.
[202] Andrew H. Miller,et al. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders , 2017, Neuropsychopharmacology.
[203] Zhengxue Qiao,et al. CREB1 gene polymorphisms combined with environmental risk factors increase susceptibility to major depressive disorder (MDD). , 2015, International journal of clinical and experimental pathology.
[204] D. Steffens,et al. Basolateral amygdala volume and cell numbers in major depressive disorder: a postmortem stereological study , 2014, Brain Structure and Function.
[205] T. Hansen,et al. Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. , 2012, Journal of affective disorders.
[206] Andrew H. Miller,et al. Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior , 2012, Neuropsychopharmacology.
[207] G. Martino,et al. Animal models of multiple sclerosis. , 2009, Methods in molecular biology.
[208] R. Dantzer,et al. From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.
[209] Andrew H. Miller,et al. Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.
[210] T. J. Nickola,et al. Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. , 2001, The Journal of pharmacology and experimental therapeutics.